-
Product Insights
Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026" provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
B-Cell Non-Hodgkin's Lymphoma Epidemiology Analysis and Forecast to 2033
Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008). NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes....
-
Product Insights
Burkitt Lymphoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Burkitt Lymphoma Clinical Trial Report Overview A total of 474 Burkitt lymphoma clinical trials were conducted as of November 2024. The Burkitt lymphoma clinical trial report provides a comprehensive understanding of the Burkitt lymphoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North...
-
Product Insights
Marginal Zone B-cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
Burkitt Lymphoma - Drugs In Development, 2024
Empower your strategies with our Burkitt Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in...
-
Product Insights
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) - Drugs In Development, 2024
Empower your strategies with our Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Extranodal marginal zone B-cell lymphoma (EMZL), also known as mucosa-associated lymphoid tissue (MALT) lymphoma, is a rare type of non-Hodgkin lymphoma that originates in the marginal zone B cells outside of the lymph nodes. It often develops in various extranodal sites of the body, particularly mucosal tissues such as the stomach, salivary glands, lungs,...
-
Product Insights
Nodal Marginal Zone B-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Nodal marginal zone B-cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that affects the lymph nodes. It is a slow-growing cancer that can sometimes become aggressive. NMZL is more common in older adults, but it can occur in younger people as well. The exact cause of NMZL is unknown, but some genetic factors may be involved. NMZL...
-
Product Insights
Splenic Marginal Zone B-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Splenic marginal zone lymphoma (SMZL) is a rare type of B-cell lymphoma that affects the spleen, bone marrow, and sometimes the blood. It is a low-grade neoplasm that originates from the germinal centers of the splenic white pulp. The neoplastic cells are small lymphocytes and larger transformed lymphoblasts that invade the mantle and marginal zones of the spleen and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.